Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Craig W. Stevens

Dr. Craig W. Stevens

Health System Chair, Department of Radiation Oncology

Dr. Craig Stevens is the department chair for radiation oncology at the Beaumont Cancer Center in Royal Oak, Michigan, and a specialist in the treatment of malignant pleural mesothelioma.

Get in touch
Jump to a Topic:

About Craig W. Stevens

Accolades
  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Top Doctor icon

    Top Doctor

  • Research Excellence icon

    Excellence in Research

  • Team Leader icon

    Team Leader

  • 20+ Years of Experience icon

    20+ Years of Experience

Get to Know Dr. Craig Stevens

Radiation oncologist Dr. Craig W. Stevens specializes in treating thoracic diseases, including lung cancer and pleural mesothelioma, at the Beaumont Cancer Center in Royal Oak, Michigan.

Stevens has been a pioneer in the development of state-of-the-art Intensity Modulated Radiation Therapy (IMRT), which irradiates tumors with greater precision to avoid damaging surrounding tissue and organs.

His innovative efforts have contributed to IMRT becoming part of the multidisciplinary treatment of mesothelioma at specialty cancer centers.

Stevens is also part of the lung cancer screening program at Beaumont that can help save lives through early detection. The program is recommended for older, high-risk patients and involves low-dose CT scans.

In 2014, after nearly a decade at the Moffitt Cancer Center in Tampa, Florida, Stevens joined Beaumont to oversee the expansion of its mesothelioma treatment program.

Specialties of Dr. Craig Stevens

Dr. Craig Stevens’ Experience and Medical Education

  • Beaumont Cancer Center

  • Moffitt Cancer Center

  • M.D. Anderson Cancer Center

  • Abramson Cancer Center

  • MedStar Georgetown University Hospital (Fellowship, residency, internship)

  • Northwestern University Feinberg School of Medicine

Awards and Other Recognitions

  • American Cancer Society Career Development Award

  • Patients’ Choice Award

  • Top Doctor Award

  • Board certified in radiation oncology

Mesothelioma Clinical Trials Under Dr. Craig Stevens

  • A phase I clinical trial to collect and analyze data from patients being treated with various forms of radiation therapy and determine strategies to improve outcomes and decrease toxicities at participating institutions.

  • A phase III clinical trial comparing immunotherapy drugs when given with chemotherapy and radiation for newly diagnosed patients with Hodgkin lymphoma.

Asbestos.com Mesothelioma Guide

Get a Free Mesothelioma Guide

Free information, books, wristbands and more for patients and caregivers.

Get Your Free Guide

Dr. Stevens Is Building a Mesothelioma Treatment Program at Beaumont

Joining Beaumont in 2014 to build a mesothelioma specialty program made perfect sense to Stevens.

For years, Michigan has been ranked among the top 10 states in the country for most cases of mesothelioma, which is typically caused by long-ago occupational exposure to asbestos.

The auto industry, once huge in the state, plus the shipping industry and past reliance on manufacturing, all have played a major role in the large number of cases there.

“There was a need in the state for a real mesothelioma program,” Stevens said. “You need to have enough experience with this disease to know how to handle it best. Patients can do well with it, if managed properly. If it’s not treated correctly, which happens too often in many places, the results are not good.”

See More Top Mesothelioma Doctors

Publications of Dr. Craig Stevens

  • Dilling, T.J. et al. (2014, September 10) Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics.

  • Bepler, G. et al. (2011). Phase II Trial of Induction Gemcitabine and Carboplatin Followed by Conformal Thoracic Radiation to 74 Gy with Weekly Paclitaxel and Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology.

  • Stevens, C.W. et al. (2005). Treatment planning system evaluation for mesothelioma IMRT. Lung Cancer.

  • Liu, H.H. et. al. (2004, March 15). Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics.

Disclaimer: Dr. Craig W. Stevens has no professional affiliation with Asbestos.com.

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Asbestos.com Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by

5 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified July 31, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now